{"url_path":"/sec/sndx/8-k/2026-07-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1395937/0001193125-26-302608-index.html","accession_number":"0001193125-26-302608","cik":"0001395937","ticker":"SNDX","issuer_name":"Syndax Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1395937/0001193125-26-302608-index.html","primary_entity_key":"0001395937","primary_entity_name":"Syndax Pharmaceuticals Inc"},"word_count":161,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\n \n\nOn July 14, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation highlighting its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D event held on July 14, 2026. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.\n\n \n\nThe information contained in this Item 8.01 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}